Platelet-derived growth factors from a single donor by apheresis and one freeze–thaw cycle for treating medication-related osteonecrosis of the jaw
[EN] To assess whether the use of allogeneic platelet-derived growth factors could serve as a feasible, effective and safe biological therapy for the treatment of medication-related osteonecrosis of the jaw (MRONJ). Materials & methods: Patients with multiple myeloma and MRONJ were included and...
| Autores: | , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2022 |
| País: | España |
| Institución: | Universidad Rey Juan Carlos |
| Repositorio: | BULERIA. Repositorio Institucional de la Universidad de León |
| OAI Identifier: | oai:buleria.unileon.es:10612/19452 |
| Acceso en línea: | https://www.futuremedicine.com/doi/10.2217/rme-2022-0126 https://hdl.handle.net/10612/19452 |
| Access Level: | acceso abierto |
| Palabra clave: | Fisioterapia Al-PRP Medication-related Osteonecrosis of the jaw MRONJ Multiple myeloma PDGF Platelet-derived growth factor |
| Sumario: | [EN] To assess whether the use of allogeneic platelet-derived growth factors could serve as a feasible, effective and safe biological therapy for the treatment of medication-related osteonecrosis of the jaw (MRONJ). Materials & methods: Patients with multiple myeloma and MRONJ were included and treated with allogeneic platelet-rich plasma, continued for between 6 and 18 weeks (mean: 9). Results: We observed a treatment success rate of 87.5% (p < 0.05). Assessing the association between healing and treatment duration, we observed a statistically significant relationship (χ2 = 8.00; p = 0.018; Cramer’s V = 1), confirming that healing was very closely related to the duration of the treatment. Conclusion: Allogeneic platelet-rich plasma could be a recommended treatment for MRONJ. Future research with a large sample to validate our findings is required. |
|---|